



KPMG  
8th Floor, Prince's Building  
Central, Hong Kong  
G P O Box 50, Hong Kong  
Telephone +852 2522 6022  
Fax +852 2845 2588  
Internet kpmg.com/cn

The Board of Directors  
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.  
No. 38 Binjiang Road  
Yidu, Yichang  
Hubei, the PRC

30 June 2025

Dear Sirs

We refer to the composite document dated 30 June 2025 in connection with the proposed conditional privatisation of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “Company”) by Sunshine Lake Pharma Co., Ltd. by way of merger by absorption (the “Composite Document”), a copy of which is attached and stamped by us on its front cover for the purpose of identification.

We hereby confirm that we have given and have not withdrawn our consent to the inclusion of our report dated 30 June 2025 on the profit estimate of the Company and its subsidiaries in accordance with Rule 10 of the Code on Takeovers and Mergers issued by the Securities and Futures Commission in the Composite Document, and the references to our name in the form and context in which they are included.



Yours faithfully

KPMG

Certified Public Accountants  
Hong Kong



KPMG  
8th Floor, Prince's Building  
Central, Hong Kong  
G P O Box 50, Hong Kong  
Telephone +852 2522 6022  
Fax +852 2845 2588  
Internet kpmg.com/cn

The Board of Directors  
Sunshine Lake Pharma Co., Ltd.  
1 Industrial North Road  
Songshan Lake Park  
Dongguan City  
Guangdong Province, the PRC

30 June 2025

Dear Sirs

We refer to the composite document dated 30 June 2025 in connection with the proposed conditional privatisation of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. by Sunshine Lake Pharma Co., Ltd. (the "Offeror") by way of merger by absorption (the "Composite Document"), a copy of which is attached and stamped by us on its front cover for the purpose of identification.

We hereby confirm that we have given and have not withdrawn our consent to (a) the reproduction of our report dated 10 May 2024 on the discounted future cash flows for the valuation report dated 10 May 2024 appended to the announcement dated 10 May 2024 and (b) the inclusion of (1) our report dated 30 June 2025 on the discounted future cash flows for the valuation report dated 30 June 2025; (2) our report dated 30 June 2025 on the profit estimate of the Offeror and its subsidiaries in accordance with Rule 10 of the Code on Takeovers and Mergers issued by the Securities and Futures Commission in the Composite Document, and the references to our name in the form and context in which they are included.

It should be noted that we have not performed an assurance engagement in accordance with any assurance standard on the discounted future cash flows as set out in the valuation report dated 10 May 2024 subsequent to 10 May 2024. This consent should not be construed as in any way updating or refreshing our report dated 10 May 2024 on the discounted future cash flows for the valuation report dated 10 May 2024, nor do we accept responsibility for such report beyond that owed to those to whom the report was addressed by us at the date of its issue.



Yours faithfully

KPMG

Certified Public Accountants  
Hong Kong